UCB SA (OTCMKTS:UCBJY) Short Interest Down 50.0% in December

UCB SA (OTCMKTS:UCBJY) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 400 shares, a drop of 50.0% from the December 15th total of 800 shares. Based on an average trading volume of 28,700 shares, the days-to-cover ratio is currently 0.0 days.

Several analysts have recently commented on UCBJY shares. Barclays cut UCB from an “overweight” rating to an “equal weight” rating in a report on Tuesday, October 19th. UBS Group cut UCB from a “buy” rating to a “sell” rating in a report on Thursday. Finally, Citigroup cut UCB from a “buy” rating to a “neutral” rating in a report on Monday, January 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $52.84.

OTCMKTS UCBJY opened at $50.52 on Friday. UCB has a 1-year low of $44.41 and a 1-year high of $61.96. The business has a 50 day moving average price of $56.01 and a 200 day moving average price of $56.17.

UCB Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Recommended Story: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.